RE:The Nasdaq listingI'm guessing KNR will let the share price run for a while, after some sales contracts are announced, and then raise money at a much higher share price. That would be ideal.
pointer wrote: I see only one issue with listing in the US, and that is our tight free float. If the goal is to attract US institutional investors, they would have no way of buying without driving the share price through the roof. Even if we split, if someone wanted $10 million worth of shares, the effect would be the same.
KNR could do a PP, and give it all to big buyers. But if BioCloud is as profitable as we hope, we simply don't need the money. And there are two problems with that. It would pizz us off, and dilute both us and KNR's largest shareholder, Paul. So that may, or may not, happen.
But one thing the Nasdaq listing would do, is expose us to a whole new world of US investors, and that would be a very big deal indeed. That could be when we really see the share price reflect the emerging reality.
One thing for sure, anyone selling today is either a daytrader, or simply nuts! :o)